Showing 1281-1290 of 7862 results for "".
A New Era in Hidradenitis Suppurativa Care
https://practicaldermatology.com/topics/rare-disease/a-new-era-in-hidradenitis-suppurativa-care/56428/Remarkable innovation is happening in HS. Ultimately, it comes down to this: we are now able to provide patients with a level of care that was not previously possible because so many new therapies are being unlocked.10 Procedural Tips for Hidradenitis Suppurativa
https://practicaldermatology.com/topics/rare-disease/10-procedural-tips-for-hidradenitis-suppurativa/56430/This guide was created to assist dermatologists who care for patients with HS considering surgery and emphasizes the importance of patient-centered care, expectation setting, and advanced surgical techniques.GLP-1RAs and the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1ras-and-the-dermatologist/48885/We are only beginning to understand the implications of GLP-1s for skin and systemic health. These medications are here to stay, and dermatology must be part of the conversation.A Guide to Building Lifelong Patient Loyalty
https://practicaldermatology.com/issues/october-2025/a-guide-to-building-lifelong-patient-loyalty/39758/Interest in medical aesthetic treatments continues to grow and signs indicate that demand will remain strong. Today’s patients are more informed and educated than ever and are seeking personalized, high-quality experiences.Preparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuFrom Training to Transformation: How Leaders Get the Most Out of Educating Their Team
https://practicaldermatology.com/issues/september-2025/from-training-to-transformation-how-leaders-get-the-most-out-of-educating-their-team/37640/Imagine investing thousands of dollars in staff time and tuition for the latest aesthetic techniques or business courses—sending employees to conferences or bringing in an expert for in-office training—only to watch those skills fade, or be underused or forgotten.Busy by Design Plans: How to Use Downtime to Drive Revenue and Make Uptime Smoother for Your Team
https://practicaldermatology.com/issues/september-2025/busy-by-design-plans-how-to-use-downtime-to-drive-revenue-and-make-uptime-smoother-for-your-team/37641/In today’s fast-paced dermatology industry, treatments can sometimes feel more transactional than transformational.The ESOP Model: An Alternative to PE for Dermatology Practices
https://practicaldermatology.com/issues/september-2025/the-esop-model-an-alternative-to-pe-for-dermatology-practices/37637/Not all practice models are as simple as private practice vs private equity. At Ada West Dermatology in Boise, Idaho, we’ve adopted a somewhat uncommon business model called an employee stock ownership plan (ESOP) and it’s worked very well for us.Spotlight on COVID-19 Related Hair Loss
https://practicaldermatology.com/topics/hair-nails/spotlight-on-covid-19-related-hair-loss/23667/CSF faculty members discuss COVID-19 related hair loss, its treatments, and its implications